Roche has launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time.
The common respiratory illnesses include influenza A, influenza B and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new respiratory test panels, designed to test influenza and other common respiratory illnesses, can be run together or alone using one nasopharyngeal swab specimen.
They use a real-time PCR nucleic acid amplification method to detect specific DNA sequences obtained after extraction.
This helps to achieve quick detection and specific measurement of genes from microorganisms that are associated with infectious diseases, cancer and genetic abnormalities.
Roche stated that the flexible syndromic-style test panel provides clinicians with actionable insights sooner when compared to conventional methods and also reduces unnecessary testing.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition to improving patient care, the test helps with proper hospital bed management and infection control.
Roche Diagnostics CEO Thomas Schinecker said: “Our latest set of syndromic respiratory solutions allows clinicians to choose the appropriate tests based on the healthcare setting, season and patient needs.
“By testing only what is medically relevant and necessary, we enable targeted therapy, avoid misuse of antibiotics and reduce unnecessary intervention.”
The molecular PCR diagnostic test panels run on the cobas omni–Utility Channel, cobas 6800/8800 Systems.
Furthermore, the company stated that it aims to expand the availability of these tests beyond CE markets in the future.
Earlier this month, Roche entered a definitive agreement with TIB Molbiol Group to acquire all of the company’s outstanding shares to bolster its molecular diagnostics portfolio.
